Business
Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes
Partnership evolution includes strategic integration of select Novo Nordisk technologies into Aspect BiosystemsAspect will lead development, manufacturing and commercialisation, and Novo Nordisk will have defined rights to expand its role at a later stage Aspect will integrate select manufacturing and R&D capabilities and expertise from the US and Denmark into its Canada-anchored platform Bagsværd, Denmark and Vancouver, BC, Canada, 20 January 2026 – Novo Nordisk and Aspect Biosystems today anno
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Novo Nordisk A/S","displaySize":"","headline":null,"caption":"Novo Nordisk A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sq36MpNFOiz.w6RiXrpsqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Partnership evolution includes strategic integration of select Novo Nordisk technologies into Aspect Biosystems","length":111,"tagName":"p"}]},{"val":[{"type":"text","content":"Aspect will lead development, manufacturing and commercialisation, and Novo Nordisk will have defined rights to expand its role at a later stage","length":144,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":255,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Aspect will integrate select manufacturing and R&D capabilities and expertise from the US and Denmark into its Canada-anchored platform","length":139,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":139,"olType":false},{"type":"text","content":"Bagsværd, Denmark and Vancouver, BC, Canada, 20 January 2026 – Novo Nordisk and Aspect Biosystems today announced they are entering a new phase of their partnership to develop advanced cellular medicines for diabetes.","length":217,"tagName":"p"},{"type":"text","content":"Since 2023, Aspect and Novo Nordisk have collaborated to develop cellular medicines designed to replace, repair or supplement biological functions to deliver truly disease-modifying therapies. This new phase of the partnership builds on the momentum achieved in the existing collaboration. It reflects a shared mission to accelerate the development of potentially curative medicines for serious diseases.","length":404,"tagName":"p"},{"type":"text","content":"Aspect has acquired rights to stem cell-derived islet cell and hypoimmune cell engineering technologies from Novo Nordisk and will lead development, manufacturing and commercialisation. Novo Nordisk will have defined rights to expand its role in later-stage development and commercialisation.","length":292,"tagName":"p"},{"type":"text","conte...